IL10 and breast carcinoma: In murine models, the 4T1 breast cancer line triggers the proliferation of tumor-associated Bregs (123), which suppress immune responses by secreting anti-inflammatory mediators such as interleukin 10 (IL-10), interleukin 35 (IL-35), and transforming growth factor beta (TGF-β).